Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Financing Activities (2022 - 2025)

Taysha Gene Therapies' Cash from Financing Activities history spans 4 years, with the latest figure at $8.8 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 33.39% year-over-year to $8.8 million; the TTM value through Sep 2025 reached $224.7 million, up 208.65%, while the annual FY2024 figure was $76.7 million, 43.78% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $8.8 million at Taysha Gene Therapies, down from $216.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $216.3 million in Q2 2025 and bottomed at -$4.2 million in Q4 2023.
  • The 4-year median for Cash from Financing Activities is $377000.0 (2023), against an average of $32.7 million.
  • The largest YoY upside for Cash from Financing Activities was 136637.86% in 2023 against a maximum downside of 245.79% in 2023.
  • A 4-year view of Cash from Financing Activities shows it stood at $41.2 million in 2022, then crashed by 110.3% to -$4.2 million in 2023, then surged by 91.6% to -$357000.0 in 2024, then surged by 2564.15% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Cash from Financing Activities are $8.8 million (Q3 2025), $216.3 million (Q2 2025), and -$52000.0 (Q1 2025).